Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Denali Therapeutics (DNLI) Shares Issued (2017 - 2026)

Denali Therapeutics has reported Shares Issued over the past 9 years, most recently at $3.2 million for Q4 2025.

  • Quarterly Shares Issued rose 100.67% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Dec 2025, down 51.35% year-over-year, with the annual reading at $8.5 million for FY2025, 51.35% down from the prior year.
  • Shares Issued was $3.2 million for Q4 2025 at Denali Therapeutics, down from $5.2 million in the prior quarter.
  • Over five years, Shares Issued peaked at $499.3 million in Q1 2024 and troughed at -$491.5 million in Q2 2024.
  • The 5-year median for Shares Issued is $4.4 million (2022), against an average of $18.9 million.
  • The largest YoY upside for Shares Issued was 19622.11% in 2024 against a maximum downside of 10341.53% in 2024.
  • A 5-year view of Shares Issued shows it stood at $5.2 million in 2021, then surged by 5418.5% to $285.2 million in 2022, then plummeted by 98.35% to $4.7 million in 2023, then tumbled by 10341.53% to -$481.9 million in 2024, then skyrocketed by 100.67% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Shares Issued are $3.2 million (Q4 2025), $5.2 million (Q3 2025), and -$595000.0 (Q2 2025).